Novo Nordisk Aims for U.S. Approval for Tresiba

Jan. 31 (Bloomberg) -- Bloomberg's Caroline Hyde reports that Novo Nordisk A/S stuck to its target of getting U.S. approval for the diabetes treatment Tresiba in the first half as it’s counting on the product to reach higher 2013 forecasts. She speaks on Bloomberg Television's "The Pulse."